Andrew J Armstrong
Overview
Explore the profile of Andrew J Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
306
Citations
11572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401283.
PMID: 40043230
Purpose: The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov...
2.
Sharifi M, Sperger J, Taylor A, Tippins K, Reese S, Carreno V, et al.
Cancer Discov
. 2025 Feb;
PMID: 39912912
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance...
3.
Shore N, Armstrong A, Barata P, Byrne L, Hafron J, Young S, et al.
Urology
. 2025 Feb;
PMID: 39909130
Objective: To advocate for universal germline genetic testing (UGGT) in prostate cancer and provide practical recommendations for its implementation. Methods: Although guidelines for germline genetic testing in prostate cancer have...
4.
5.
Al Abo M, Foo W, Howard L, McGue S, Lacroix B, Kephart J, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):30.
PMID: 39880920
Black men suffer disproportionately from prostate cancer (PCa) compared to men of other races and ethnicities. Comparing the molecular landscape of PCa among Black and White patients has the potential...
6.
Hwang J, Hwang J, Holl E, Holl E, Wu Y, Agarwal A, et al.
JCI Insight
. 2025 Jan;
10(4).
PMID: 39773530
Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression...
7.
Shore N, Nielsen S, Esplin E, Antonarakis E, Barata P, Beer T, et al.
JCO Oncol Pract
. 2024 Dec;
OP2400626.
PMID: 39700441
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become...
8.
Knutson T, Luo B, Kobilka A, Lyman J, Guo S, Munro S, et al.
Nat Commun
. 2024 Dec;
15(1):10648.
PMID: 39663356
Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant...
9.
Barnett R, Jang A, Lanka S, Fu P, Bucheit L, Babiker H, et al.
Commun Med (Lond)
. 2024 Dec;
4(1):256.
PMID: 39623081
Background: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to...
10.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...